期刊
ANNALS OF ONCOLOGY
卷 19, 期 4, 页码 807-813出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdm510
关键词
angiogenesis; bevacizumab; children; refractory solid tumors
类别
Background: The aim of this study was to evaluate feasibility and toxicity of bevacizumab (Avastin (R)), a monoclonal antibody directed against the vascular endothelial growth factor in children and young adults. Patients and methods: Fifteen patients (male: n=8; female: n=7; median age, 14.6 years) received bevacizumab for recurrent or progressive solid tumors (carcinoma: n=3; neuroblastoma: n=2; astrocytoma grade III: n=2; rhabdomyosarcoma: n=2; nephroblastoma: n=2; benign vascular tumors: n=2; synovial sarcoma: n=1; and malignant hemangiopericytoma: n=1) on a compassionate basis. Bevacizumab was administered at 5 - 10 mg/ kg body weight intravenously every 2 - 3 weeks. Most patients received chemotherapy in addition to bevacizumab. Duration of bevacizumab therapy ranged from 1.5 to 23 months. Results: Bevacizumab- related side- effects were mild and included hypertonia (n=2), proteinuria/ hematuria (n=2), epistaxis (n=2), local erythema (n=1), and defective wound healing and ascites (n=1). Radiographic objective responses (partial responses) were observed in two patients with astrocytoma grade III and in one patient each with neuroblastoma and pleomorphic rhabdomyosarcoma, respectively. Conclusions: Bevacizumab seems to have a good acute safety profile and some antitumor activity in heavily pretreated children and young adults with recurrent solid tumors. Prospective clinical trials are urgently needed to further evaluate the safety and efficacy of bevacizumab in pediatric patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据